Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
11.68 AUD | -0.34% | -1.60% | -4.50% |
Apr. 30 | Evotec, Bayer to Focus on Precision Treatments for Cardiovascular Diseases | MT |
Apr. 24 | Germany's Evotec Appoints Permanent CEO | MT |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- With relatively low growth outlooks, the group is not among those with the highest revenue growth potential.
- The company's currently anticipated earnings per share (EPS) growth for the next few years is a notable weakness.
- The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 72.6 times its estimated earnings per share for the ongoing year.
- The company is highly valued given the cash flows generated by its activity.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- Revenue estimates are regularly revised downwards for the current and coming years.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Leisure & Recreation
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-4.50% | 1.27B | C | ||
+5.30% | 4.14B | D+ | ||
+25.48% | 2.12B | C | ||
-.--% | 1.66B | - | ||
-28.10% | 1.62B | D | ||
-20.10% | 1.56B | C+ | ||
-13.16% | 1.36B | - | ||
-12.53% | 1.14B | C- | ||
-21.48% | 1.11B | - | ||
-.--% | 818M | - | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- EVT Stock
- Ratings EVT Limited